메뉴 건너뛰기




Volumn 106, Issue 2, 1998, Pages 103-107

Overnight GLP-1 normalizes lasting but not daytime plasma glucose levels in NIDDM patients

Author keywords

GLP 1 (7 36 amide); Glucagon; Incretin; Insulin; Pharmacokinetics

Indexed keywords

C PEPTIDE; GLIBENCLAMIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; METFORMIN;

EID: 0031979642     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0029-1211959     Document Type: Article
Times cited : (21)

References (25)
  • 1
    • 0017362711 scopus 로고
    • Diabetes: The quest for basal normoglycaemia
    • Holman RR, Turner RC: Diabetes: The quest for basal normoglycaemia. The Lancet I: 469-474, 1977
    • (1977) The Lancet , vol.1 , pp. 469-474
    • Holman, R.R.1    Turner, R.C.2
  • 2
    • 0019416827 scopus 로고
    • The basal plasma glucose: A simple relevant index of maturity-onset diabetes
    • Holman RR, Turner RC: The basal plasma glucose: A simple relevant index of maturity-onset diabetes. Clin Endocrinol 14: 279-286, 1980
    • (1980) Clin Endocrinol , vol.14 , pp. 279-286
    • Holman, R.R.1    Turner, R.C.2
  • 3
    • 0020456354 scopus 로고
    • Evidence that peak II GLI or enteroglucagon is identical to the C-terminal sequence (residues 33-69) of glicentin
    • Holst JJ: Evidence that peak II GLI or enteroglucagon is identical to the C-terminal sequence (residues 33-69) of glicentin. Biochem J 207: 381-388, 1982
    • (1982) Biochem J , vol.207 , pp. 381-388
    • Holst, J.J.1
  • 4
    • 0026502473 scopus 로고
    • Effects of a combination of bedtime intermediate-acting insulin and glibenclamide in Type II (non-insulin-dependent) diabetic patients with secondary failure to respond to oral hypoglycaemic agents
    • Krempf M, Godeau T, Ranganathan S, Blanchard P, Ritz R, Chabonnel B: Effects of a combination of bedtime intermediate-acting insulin and glibenclamide in Type II (non-insulin-dependent) diabetic patients with secondary failure to respond to oral hypoglycaemic agents. Eur J Clin Pharmacol 42: 281-286, 1992
    • (1992) Eur J Clin Pharmacol , vol.42 , pp. 281-286
    • Krempf, M.1    Godeau, T.2    Ranganathan, S.3    Blanchard, P.4    Ritz, R.5    Chabonnel, B.6
  • 5
    • 0023638829 scopus 로고
    • Glucagon-like peptide 1 (7-36): A physiological incretin in man
    • Kreymann B, Ghatei MA, Williams G, Bloom SR: Glucagon-like peptide 1 (7-36): a physiological incretin in man. Lancet II: 1300-1304, 1987
    • (1987) Lancet , vol.2 , pp. 1300-1304
    • Kreymann, B.1    Ghatei, M.A.2    Williams, G.3    Bloom, S.R.4
  • 6
    • 0026542396 scopus 로고
    • Insulinotropic action of glucagon-like peptide-I-(7-37) in diabetic and nondiabetic subjects
    • Nathan DM, Schreiber E, Fogel H, Mojsov S, Habener JF: Insulinotropic action of glucagon-like peptide-I-(7-37) in diabetic and nondiabetic subjects. Diabetes Care 15: 270-276, 1992
    • (1992) Diabetes Care , vol.15 , pp. 270-276
    • Nathan, D.M.1    Schreiber, E.2    Fogel, H.3    Mojsov, S.4    Habener, J.F.5
  • 7
    • 0027419106 scopus 로고
    • Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide 1 (7-36 amide) infused at near-physiological insulinotropic hormone and glucose concentrations
    • Nauck M, Bartels E, Ørskov C, Ebert R, Creutzfeldt W: Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide 1 (7-36 amide) infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 76: 912-917, 1993a
    • (1993) J Clin Endocrinol Metab , vol.76 , pp. 912-917
    • Nauck, M.1    Bartels, E.2    Ørskov, C.3    Ebert, R.4    Creutzfeldt, W.5
  • 8
    • 7144250388 scopus 로고
    • Inhibition of gastric emptying by GLP-1 (7-36 amide) or (7-37): Effects on postprandial glycaemia and insulin secretion
    • Nauck MA, Ettler R, Niedereichholz U, Ørskov C, Holst JJ, Schmiegel W: Inhibition of gastric emptying by GLP-1 (7-36 amide) or (7-37): Effects on postprandial glycaemia and insulin secretion (abstract). Gut 37 (Suppl. 2): A 124, 1995
    • (1995) Gut , vol.37 , Issue.2 SUPPL.
    • Nauck, M.A.1    Ettler, R.2    Niedereichholz, U.3    Ørskov, C.4    Holst, J.J.5    Schmiegel, W.6
  • 9
    • 0027391607 scopus 로고
    • Preserved incretin activity of glucagon-like peptide 1 (GLP-1) (7-36 amide) but not of synthetic human gastric inhibitory polypeptide (GIP) in patients with NIDDM mellitus
    • Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W: Preserved incretin activity of glucagon-like peptide 1 (GLP-1) (7-36 amide) but not of synthetic human gastric inhibitory polypeptide (GIP) in patients with NIDDM mellitus. J Clin Invest 91: 301-307, 1993b
    • (1993) J Clin Invest , vol.91 , pp. 301-307
    • Nauck, M.A.1    Heimesaat, M.M.2    Ørskov, C.3    Holst, J.J.4    Ebert, R.5    Creutzfeldt, W.6
  • 10
    • 0027248866 scopus 로고
    • Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients
    • Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W: Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36: 741-744, 1993c
    • (1993) Diabetologia , vol.36 , pp. 741-744
    • Nauck, M.A.1    Kleine, N.2    Ørskov, C.3    Holst, J.J.4    Willms, B.5    Creutzfeldt, W.6
  • 11
    • 0026659679 scopus 로고
    • Glucagon-like peptide-1, a new hormone of the entero-insular axis
    • Ørskov C: Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia 35: 701-711, 1992
    • (1992) Diabetologia , vol.35 , pp. 701-711
    • Ørskov, C.1
  • 12
    • 0023104848 scopus 로고
    • Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2)
    • Ørskov C, Holst JJ: Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2). Scand J Clin Lab Invest 47: 165-174, 1987
    • (1987) Scand J Clin Lab Invest , vol.47 , pp. 165-174
    • Ørskov, C.1    Holst, J.J.2
  • 13
    • 0028281773 scopus 로고
    • Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide 1 in humans
    • Ørskov C, Rabenhøj L, Wettergren A., Kofod H, Holst JJ: Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide 1 in humans. Diabetes 43: 535-539, 1994
    • (1994) Diabetes , vol.43 , pp. 535-539
    • Ørskov, C.1    Rabenhøj, L.2    Wettergren, A.3    Kofod, H.4    Holst, J.J.5
  • 14
    • 0028904931 scopus 로고
    • Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) (7-36 amide) in the fasting state in healthy subjects
    • Qualmann, C, Nauck MA, Holst JJ, Ørskov C, W Creutzfeldt. Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) (7-36 amide) in the fasting state in healthy subjects. Acta Diabetol 32: 13-16, 1995
    • (1995) Acta Diabetol , vol.32 , pp. 13-16
    • Qualmann, C.1    Nauck, M.A.2    Holst, J.J.3    Ørskov, C.4    Creutzfeldt, W.5
  • 15
    • 0031033531 scopus 로고    scopus 로고
    • Near-normalization of diurnal glucose concentrations by continous administration of glucagon-like peptide 1 (GLP-1) in subjects with NIDDM
    • Rachman J, Barrow BA, Levy JC, Turner RC: Near-normalization of diurnal glucose concentrations by continous administration of glucagon-like peptide 1 (GLP-1) in subjects with NIDDM. Diabetologia 40: 205-211, 1997
    • (1997) Diabetologia , vol.40 , pp. 205-211
    • Rachman, J.1    Barrow, B.A.2    Levy, J.C.3    Turner, R.C.4
  • 16
    • 0029909112 scopus 로고    scopus 로고
    • Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM
    • Rachman J, Gribble FM, Barrow BA, Levy JC, Buchanan KD, Turner RC: Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM. Diabetes 45: 1524-1530, 1996
    • (1996) Diabetes , vol.45 , pp. 1524-1530
    • Rachman, J.1    Gribble, F.M.2    Barrow, B.A.3    Levy, J.C.4    Buchanan, K.D.5    Turner, R.C.6
  • 17
    • 0021959922 scopus 로고
    • New tactics for type II diabetes: Regimens based on intermediate-acting insulin taken at bedtime
    • Riddle MC: New tactics for type II diabetes: regimens based on intermediate-acting insulin taken at bedtime. Lancet 1: 192-195, 1985
    • (1985) Lancet , vol.1 , pp. 192-195
    • Riddle, M.C.1
  • 18
    • 0024432987 scopus 로고
    • Efficacy of bedtime NPH insulin with daytime sulfonylurea for a subpopulation of Type II diabetes
    • Riddle MC, Hart JS, Bouma DJ, Philipson BE, Youker G: Efficacy of bedtime NPH insulin with daytime sulfonylurea for a subpopulation of Type II diabetes. Diabetes Care 12: 623-629, 1989
    • (1989) Diabetes Care , vol.12 , pp. 623-629
    • Riddle, M.C.1    Hart, J.S.2    Bouma, D.J.3    Philipson, B.E.4    Youker, G.5
  • 19
    • 0028959214 scopus 로고
    • Bedtime insulin/ daytime glipizide: Effective therapy for sulfonylurea failures in NIDDM
    • Shank ML, Del Prato S, De Fronzo RA. Bedtime insulin/ daytime glipizide: Effective therapy for sulfonylurea failures in NIDDM. Diabetes 44: 165-172, 1995
    • (1995) Diabetes , vol.44 , pp. 165-172
    • Shank, M.L.1    Del Prato, S.2    De Fronzo, R.A.3
  • 21
    • 3543143570 scopus 로고
    • Prolonged normalization of fasting hyperglycaemia by intravenous GLP-1 ((7-36 amide) or (7-37)) in NIDDM patients
    • Weber I, Bach-Esser, A-K, Bach I, Richter S, Orskov C, Holst JJ, Schmiegel W, Nauck MA: Prolonged normalization of fasting hyperglycaemia by intravenous GLP-1 ((7-36 amide) or (7-37)) in NIDDM patients (abstract). Diabetologia 38 (Suppl. 1): A 171, 1995
    • (1995) Diabetologia , vol.38 , Issue.1 SUPPL.
    • Weber, I.1    Bach-Esser, A.-K.2    Bach, I.3    Richter, S.4    Orskov, C.5    Holst, J.J.6    Schmiegel, W.7    Nauck, M.A.8
  • 23
    • 7144256360 scopus 로고    scopus 로고
    • Overnight GLP-1 (7-36 amide), daytime oral agents: Failure to lower postprandial glucose by normalizing fasting values in NIDDM patients
    • Willms B, Idowu K, Holst JJ, Nauck MA: Overnight GLP-1 (7-36 amide), daytime oral agents: Failure to lower postprandial glucose by normalizing fasting values in NIDDM patients. Diabetes 45 (Suppl. 2): 301A, 1996a
    • (1996) Diabetes , vol.45 , Issue.2 SUPPL.
    • Willms, B.1    Idowu, K.2    Holst, J.J.3    Nauck, M.A.4
  • 24
    • 0030068620 scopus 로고    scopus 로고
    • Gastric emptying, glucose responses and insulin secretion after a liquid test meal: Effects of exogenous glucagon-like peptide 1 (GLP-1) (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients
    • Willms B, Werner J, Holst JJ, Ørskov C, Creutzfeldt W, Nauck MA: Gastric emptying, glucose responses and insulin secretion after a liquid test meal: Effects of exogenous glucagon-like peptide 1 (GLP-1) (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients. J Clin Endocrinol Metab 81: 327-332, 1996b
    • (1996) J Clin Endocrinol Metab , vol.81 , pp. 327-332
    • Willms, B.1    Werner, J.2    Holst, J.J.3    Ørskov, C.4    Creutzfeldt, W.5    Nauck, M.A.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.